Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors

New England Journal of Medicine

Volumn 341, Issue 5, 1999, Pages 319-327

  Lincoff, A Michael ^a   Califf, Robert M ^b   Moliterno, David J ^a   Ellis, Stephen G ^a   Ducas, John ^c   Kramer, Jeffrey H ^d   Kleiman, Neal S ^e   Cohen, Eric A ^j   Booth, Joan E ^a   Sapp, Shelly K ^a   Cabot, Catherine F ^f   Topol, Eric J ^a   Tcheng, James E ^j   Talley, J David ^g   Caramori, Paul O ^j   Burton, Jeffrey R ^h   Kelly, Thomas A ⁱ   Ivanc, Tom B ^j  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d OUR LADY OF LOURDES MEDICAL CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f CENTOCOR INC   (United States)

^g UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^h UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

ⁱ MOSES H CONE MEMORIAL HOSPITAL   (United States)

^j Moses Cone Memorial Hospital ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; TICLOPIDINE;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DEATH; DIABETES MELLITUS; DRUG EFFICACY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RESTENOSIS; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DIABETES COMPLICATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INCIDENCE; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECURRENCE; SINGLE-BLIND METHOD; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 0033615009     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199907293410503     Document Type: Article

References (19)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
2. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
3. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35. [Erratum, Lancet 1997;350:744.]
4. Serruys PW, de Jaegere P, Kiemeneij; F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
5. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
6. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stcnts with balloon angioplasty in selected patients with coronary artery disease. Lancet 1998;352:673-81. [Erratum, Lancet 1998;352:1478.]
7. Erbel R, Haude M, Höpp HW, et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. N Engl J Med 1998;339:1672-8.
8. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
9. Mancini GBJ, Simon SB, McGillem MJ, LeFree MT, Friedman HZ, Vogel RA. Automated quantitative coronary arteriography: morphologic and physiologic validation in vivo of a rapid digital angiographic method. Circulation 1987;75:452-60. [Erratum, Circulation 1987;75:1199.]
10. Princas RJ, Crow RS, Blackburn H. The Minnesota code manual of electrocardiographic findings: standards and procedures for measurement and classification. Boston: John Wright-PSG, 1982.
11. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa intcgrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
12. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 block-ade with percutaneous coronary intervention. JAMA 1997;278:479-84.
13. Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial: Evaluation of PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 1999;99:1951-8.
14. Mintz GS, Popma JJ, Hong MK, et al. Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis. Am J Cardiol 1996;78:18-22.
15. Lau K-W, Gao W, Ding Z-P, Kwok V. Single bailout stenting for threatened coronary closure complicating balloon angioplasty: acute and mid-term outcome. Coron Artery Dis 1996;7:327-33.
16. Wong SC, Baim DS, Schatz RA, et al. Immediate results and late out-comes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-Schatz stent experience. J Am Coll Cardiol 1995;26: 704-12.
17. Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993;118:344-9.
18. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: a serial intravascular ultrasound study. Circulation 1997;95: 1366-9.
19. 3 integrins. Circulation 1998;98:1085-91.